HDM1002

DRUG3 trials

Sponsors

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Conditions

Healthy Adult SubjectHealthy SubjectsOverweight Subject

Phase 1

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

Not yet recruitingNCT06601517

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Healthy Adult Subject, Overweight Subject

Start: 2024-10-31End: 2025-04-30Target: 30Updated: 2024-09-23

A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects

Not yet recruitingNCT06608329

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Healthy Adult Subject

Start: 2024-10-31End: 2024-12-31Target: 33Updated: 2024-09-23

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

RecruitingNCT07331389

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Healthy Subjects, Overweight Subject

Start: 2025-09-24End: 2026-06-13Target: 111Updated: 2026-01-09